目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 PEPTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET, BY PRODUCT TYPE AND COUNTRY, 2023
4.3 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024 VS. 2029
4.4 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in peptide therapeutics
5.2.1.2 Innovations in peptide synthesis instruments
5.2.1.3 Growing use of peptides in diagnostics and research
5.2.2 RESTRAINTS
5.2.2.1 Regulatory hurdles
5.2.2.2 High cost of peptide synthesis and instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of personalized medicine
5.2.3.2 Strategic collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Immunogenicity issues
5.2.4.2 Environmental concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 PEPTIDE SYNTHESIS MARKET: PRODUCT MANUFACTURERS
5.7.2 PEPTIDE SYNTHESIS MARKET: SERVICE PROVIDERS
5.7.3 PEPTIDE SYNTHESIS MARKET: END USERS
5.7.4 PEPTIDE SYNTHESIS MARKET: REGULATORY BODIES
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Solid-phase peptide synthesis (SPPS)
5.9.1.2 Liquid-phase peptide synthesis (LPPS)
5.9.1.3 Enzymatic peptide synthesis
5.9.1.4 Continuous-flow peptide synthesis
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Labeling and tracking technologies
5.9.2.2 Purification techniques
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Cell-free protein synthesis
5.9.3.2 Protein design and engineering
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE DATA FOR HS CODE 902720 (CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS)
5.11.1.1 Import data for HS code 902720
5.11.1.2 Export data for HS CODE 902720
5.11.2 TRADE DATA FOR HS CODE 841933 (LYOPHILISATION APPARATUS, FREEZE DRYING UNITS AND SPRAY DRYERS)
5.11.2.1 Import data for HS code 841993
5.11.2.2 Export data for HS code 841933
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13.2 REGULATORY FRAMEWORK
5.13.2.1 North America
5.13.2.1.1 US
5.13.2.1.2 Canada
5.13.2.2 Europe
5.13.2.2.1 Germany
5.13.2.2.2 UK
5.13.2.2.3 France
5.13.2.3 Asia Pacific
5.13.2.3.1 Japan
5.13.2.3.2 China
5.13.2.4 Latin America
5.13.2.4.1 Brazil
5.13.2.5 Middle East & Africa
5.13.2.5.1 GCC Countries
5.13.2.5.2 South Africa
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 BARGAINING POWER OF SUPPLIERS
5.14.2 BARGAINING POWER OF BUYERS
5.14.3 THREAT OF NEW ENTRANTS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI/GENERATIVE AI ON PEPTIDE SYNTHESIS MARKET
5.16.1 INTRODUCTION
5.16.2 IMPACT OF AI ON PEPTIDE SYNTHESIS ECOSYSTEM
5.16.3 FUTURE OF GENERATIVE AI IN PEPTIDE SYNTHESIS ECOSYSTEM

6 PEPTIDE SYNTHESIS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 INCREASING ADOPTION OF SOLID AND LIQUID-PHASE PEPTIDE SYNTHESIS TO STIMULATE GROWTH
6.3 SERVICES
6.3.1 GROWING ADVANCEMENTS IN PEPTIDE DESIGN AND SYNTHESIS OPTIMIZATION TO FUEL MARKET

7 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 REAGENTS
7.2.1.1 Resins
7.2.1.1.1 Growing demand for therapeutic peptides to boost market
7.2.1.2 Amino acids
7.2.1.2.1 Increasing advancements in synthetic amino acid modifications to aid growth
7.2.1.3 Coupling reagents
7.2.1.3.1 Rising adoption of high-throughput peptide synthesis to expedite growth
7.2.1.4 Dyes & fluorescent labeling reagents
7.2.1.4.1 Increasing demand for high-resolution, sensitive imaging technologies to promote growth
7.2.1.5 Deprotection reagents
7.2.1.5.1 Rising complexity of modified peptides and cyclic structures to facilitate growth
7.2.1.6 Cleavage reagents
7.2.1.6.1 Increasing use of complex peptides to sustain growth
7.2.1.7 Other reagents
7.2.2 OTHER CONSUMABLES
7.3 INSTRUMENTS
7.3.1 PEPTIDE SYNTHESIZERS
7.3.1.1 Automated peptide synthesizers
7.3.1.1.1 Increasing launches of automated peptide synthesizers to promote growth
7.3.1.2 Manual peptide synthesizers
7.3.1.2.1 Growing use of peptide synthesizers for early-stage drug discovery and research to fuel market
7.3.2 CHROMATOGRAPHY SYSTEMS
7.3.2.1 Increasing shift toward high-throughput and industrial-scale peptide production to amplify growth
7.3.3 LYOPHILIZERS
7.3.3.1 Rising influence of contract manufacturing organizations to encourage growth
7.3.4 OTHER INSTRUMENTS

8 PEPTIDE SYNTHESIS SERVICES MARKET, BY TYPE
8.1 INTRODUCTION
8.2 PEPTIDE SYNTHESIS
8.2.1 RISING ADOPTION OF PERSONALIZED MEDICINES AND TARGETED THERAPIES TO INTENSIFY GROWTH
8.3 PEPTIDE PURIFICATION SERVICES
8.3.1 GROWING EMPHASIS ON HIGH-QUALITY PEPTIDES IN PHARMACEUTICAL DEVELOPMENT AND BIOTECH TO DRIVE MARKET
8.4 PEPTIDE LIBRARY SYNTHESIS
8.4.1 INCREASING FOCUS ON SYNTHETIC BIOLOGY TO AUGMENT GROWTH
8.5 PEPTIDE ANALYSIS SERVICES
8.5.1 INCREASING ADVANCEMENTS IN MASS SPECTROMETRY AND CHROMATOGRAPHY TO BOLSTER GROWTH

9 PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE
9.1 INTRODUCTION
9.2 CHEMICAL METHODS
9.2.1 SOLID-PHASE PEPTIDE SYNTHESIS
9.2.1.1 Increasing use of peptides and peptide derivatives in modern medicines use to encourage growth
9.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS
9.2.2.1 Growing advancements in purification technologies to boost market
9.2.3 OTHER CHEMICAL METHODS
9.3 BIOLOGICAL METHODS
9.3.1 RECOMBINANT DNA TECHNOLOGY
9.3.1.1 Increasing innovations in genetic engineering and synthetic biology to drive market
9.3.2 ENZYMATIC SYNTHESIS
9.3.2.1 Growing shift toward sustainable and eco-friendly manufacturing to propel market

10 PEPTIDE SYNTHESIS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 THERAPEUTIC APPLICATIONS
10.2.1 THERAPEUTIC APPLICATIONS, BY INDICATION
10.2.1.1 Cancer
10.2.1.1.1 Rising clinical trials to contribute to growth
10.2.1.2 Diabetes
10.2.1.2.1 Increasing need for diabetes management to favor growth
10.2.1.3 Obesity
10.2.1.3.1 Increasing development of next-generation weight management therapies to foster growth
10.2.1.4 Autoimmune diseases
10.2.1.4.1 Growing prevalence of rheumatoid arthritis, lupus, and multiple sclerosis to fuel market
10.2.1.5 Other diseases
10.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE
10.2.2.1 Peptide-based vaccines
10.2.2.1.1 Increasing research on infectious diseases and cancer immunotherapy to augment growth
10.2.2.2 Peptide-drug conjugates
10.2.2.2.1 Growing focus of pharmaceutical companies on drug conjugation to drive market
10.2.2.3 Peptide inhibitors
10.2.2.3.1 Rising traction for precision medicine to assist growth
10.2.2.4 Other molecules
10.3 DIAGNOSTIC APPLICATIONS
10.3.1 RISE OF PERSONALIZED MEDICINE AND POINT-OF-CARE TESTING TO ACCELERATE GROWTH
10.4 DISCOVERY & DEVELOPMENT APPLICATIONS
10.4.1 GROWING ADVANCEMENTS IN COMBINATORIAL CHEMISTRY AND HIGH-THROUGHPUT PEPTIDE LIBRARIES TO DRIVE MARKET

11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
11.2.1 INCREASING RESEARCH ON GENOMICS AND MOLECULAR BIOLOGY TO EXPEDITE GROWTH
11.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
11.3.1 SHIFT TOWARD CUSTOM AND MODIFIED PEPTIDES TO DRIVE MARKET
11.4 ACADEMIC & RESEARCH INSTITUTES
11.4.1 INCREASING FINANCIAL AND REGULATORY SUPPORT FOR RESEARCH TO SUPPORT GROWTH
11.5 MEDICAL DEVICE COMPANIES
11.5.1 BOOMING PEPTIDE-BASED DRUG DELIVERIES TO PROMOTE GROWTH
11.6 HOSPITALS & DIAGNOSTIC CENTERS
11.6.1 RISING DEMAND FOR PEPTIDE-BASED DIAGNOSTICS TO FAVOR GROWTH

12 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
12.2.1 INCREASING FOCUS ON PEPTIDE-BASED THERAPEUTICS IN ONCOLOGY AND METABOLIC DISORDERS TO INTENSIFY GROWTH
12.3 MEDICAL DEVICE COMPANIES
12.3.1 NEED TO DETECT INFECTIOUS DISEASES, CANCER, AND METABOLIC DISORDERS TO AID GROWTH
12.4 HOSPITALS & DIAGNOSTIC CENTERS
12.4.1 RISING USE OF PEPTIDE BIOMARKERS TO SUPPORT GROWTH
12.5 ACADEMIC & RESEARCH INSTITUTES
12.5.1 GROWING FOCUS ON DRUG DESIGN, VACCINE DEVELOPMENT, AND CANCER RESEARCH TO BOOST MARKET
12.6 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
12.6.1 INCREASING DEMAND FOR COST-EFFECTIVE PEPTIDE SYNTHESIS SERVICES TO FACILITATE GROWTH

13 PEPTIDE SYNTHESIS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2 US
13.2.2.1 Well-developed healthcare and research infrastructure to aid growth
13.2.3 CANADA
13.2.3.1 Increasing government funding for advanced drugs to amplify growth
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Germany to hold largest market share in Europe
13.3.3 UK
13.3.3.1 Increasing peptide synthesis research to contribute to growth
13.3.4 FRANCE
13.3.4.1 Favorable government initiatives to augment growth
13.3.5 ITALY
13.3.5.1 Growing public and private sector investments to propel market
13.3.6 SPAIN
13.3.6.1 Rising focus on advanced therapies to expedite growth
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Expanding biopharma sector to advance growth
13.4.3 JAPAN
13.4.3.1 Growing geriatric population to fuel market
13.4.4 INDIA
13.4.4.1 Increasing investments and developments in biotechnology to favor growth
13.4.5 SOUTH KOREA
13.4.5.1 Booming biotechnology sector to amplify growth
13.4.6 AUSTRALIA
13.4.6.1 Increasing government funding and initiatives to augment growth
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Growing interest in peptide-based drugs to fuel market
13.5.3 MEXICO
13.5.3.1 Increasing initiatives for stem cell research and regenerative medicine projects to foster growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Increasing government-backed investments for infrastructure to aid growth
13.6.2.2 UAE
13.6.2.2.1 High prevalence of diabetes and cardiovascular diseases to augment growth
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 INCREASING INVESTMENTS IN PHARMACEUTICAL INFRASTRUCTURE AND LIFE SCIENCE INNOVATIONS TO BOOST MARKET
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
14.3 REVENUE ANALYSIS, 2019-2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY VALUATION AND FINANCIAL METRICS
14.5.1 COMPANY VALUATION
14.5.2 FINANCIAL METRICS
14.6 BRAND/PRODUCT COMPARISON
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
14.7.5.1 Company footprint
14.7.5.2 Region footprint
14.7.5.3 Offering footprint
14.7.5.4 Technique footprint
14.7.5.5 Application footprint
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.8.1 PROGRESSIVE COMPANIES
14.8.2 RESPONSIVE COMPANIES
14.8.3 DYNAMIC COMPANIES
14.8.4 STARTING BLOCKS
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.8.5.1 Detailed list of key startups/SMEs
14.8.5.2 Competitive benchmarking of startups/SMEs
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS

15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 THERMO FISHER SCIENTIFIC INC.
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 MERCK KGAA
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 MnM view
15.1.2.3.1 Key strengths
15.1.2.3.2 Strategic choices
15.1.2.3.3 Weaknesses and competitive threats
15.1.3 AGILENT TECHNOLOGIES, INC.
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 MnM view
15.1.3.3.1 Key strengths
15.1.3.3.2 Strategic choices
15.1.3.3.3 Weaknesses and competitive threats
15.1.4 GENSCRIPT
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Expansions
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 KANEKA CORPORATION
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Expansions
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 BACHEM
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 SYNGENE INTERNATIONAL LIMITED
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.8 MESA LABS, INC.
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Product launches
15.1.8.3.2 Deals
15.1.9 BIOTAGE
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.10 CEM CORPORATION
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches
15.1.10.3.2 Deals
15.1.11 DALTON PHARMA SERVICES
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.12 BIO-SYNTHESIS INC.
15.1.12.1 Business overview
15.1.12.2 Products/Services offered
15.1.13 CSBIO
15.1.13.1 Business overviewn
15.1.13.2 Products/Services offered
15.1.14 PROTEOGENIX
15.1.14.1 Business overview
15.1.14.2 Products/Services offered
15.1.15 INNOVAGEN AB
15.1.15.1 Business overview
15.1.15.2 Products/Services offered
15.1.16 BIOSYNTH
15.1.16.1 Business overview
15.1.16.2 Products/Services offered
15.1.16.2.1 Deals
15.2 OTHER PLAYERS
15.2.1 AURIGENE PHARMACEUTICAL SERVICES LTD.
15.2.2 CORDENPHARMA
15.2.3 JPT PEPTIDE TECHNOLOGIES
15.2.4 PUROLITE
15.2.5 BIOMATIK
15.2.6 CPC SCIENTIFIC INC.
15.2.7 ADVANCED CHEMTECH, INC.
15.2.8 AMBIOPHARM INC.
15.2.9 LUXEMBOURG BIO TECHNOLOGIES
15.2.10 AAPPTEC
15.2.11 ANYGEN
15.2.12 CHEMPEP
15.2.13 PROTEOGENIX

16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS